Dmytro Kharkov

Topline DURAVYU Phase 3 data for DME expected in late 2027 as Eyepoint Pharmaceuticals advances studies

Topline DURAVYU Phase 3 data for DME expected in late 2027 as Eyepoint Pharmaceuticals advances studies
Eyepoint completes DURAVYU Phase 3 enrollment

Eyepoint Pharmaceuticals has announced the completion of patient enrollment in both pivotal Phase 3 clinical trials of its investigational therapy DURAVYU for diabetic macular edema (DME).

The company stated that topline results from these trials are anticipated in the fourth quarter of 2027, marking a significant milestone in the development of its potential ophthalmic treatment. Further updates on DURAVYU’s progress are expected as the trial results approach.

Eyepoint Pharmaceuticals recently participated in the Montreal ASRS annual meeting to discuss collaboration and innovation in retina treatment, according to a previous company update. The firm also appointed Tarek S Hassan as chief strategic science officer ahead of Phase 3 results for wet age-related macular degeneration, as detailed in an earlier announcement. These developments reflect the company's ongoing efforts to advance its position in ophthalmic therapeutics.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.